Real‐world retrospective study in elderly patients aged 65 years and older with type 2 diabetes mellitus treated with daily oral semaglutide ( SEMA ‐elderly)
Authors' conclusion
Oral semaglutide effectively improves glycaemic control and weight management in elderly patients with T2DM while improving lipid and cardiovascular parameters and proving to be safe and well tolerated.
Study context
- Population
- Patients aged ≥65 years with T2D; mean age 74.7 ± 6.1 years
- Participants
- 101 patients
- Outcome
- Change in HbA1c from baseline (V1)
- Follow-up
- Six months (V3)
Methodological detailsreal-world
- Real-world
Main finding
As reported in the abstract
Change in HbA1c · V1 to V3 (six months)
Mean HbA1c change
−0.44%
p < 0.001
Observational data: associations, not effects.
Secondary outcomes
Proportion achieving HbA1c ≤7% · V1 and V3
- At V1
- 36.6%
- At V3
- 61.7%
HbA1c reduction ≥1% and weight loss ≥5% · V3
- Proportion of patients
- 9.6%
Body weight · V1 to V3
- Mean body weight, baseline to V3
- 76.8-73.7 kg, p < 0.001
BMI, waist circumference, total cholesterol, LDL-C, systolic blood pressure · V1 to V3
- Decreased significantly from V1 to V3, with changes already evident at V2
Safety
Adverse events and discontinuation
- Patients reporting adverse events
- 11 (10.9%)
- Discontinued treatment
- 7 (6.9%)
Original publication
Real‐world retrospective study in elderly patients aged 65 years and older with type 2 diabetes mellitus treated with daily oral semaglutide ( SEMA ‐elderly). Diabetes Obes Metab. Published 10 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →